trial · primary record
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Diffuse Large B-Cell Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 543 |
| Primary completion | 2027-09-30 |
| Primary endpoint | Part 1: Number of Participants With Dose limiting Toxicities (DLTs) |
| Registry ID | NCT04663347 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:57.812Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04663347
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.